MCRPC

AcronymDefinition
MCRPCMercer County Regional Planning Commission (Pennsylvania)
MCRPCMilwaukee County Research Park Corporation (Wauwatosa, WI)
References in periodicals archive ?
It is running two Phase 2 trials for onvansertib combo therapies: one in combination with low-dose cytarabine or decitabine for acute myeloid leukemia , and another in combination with Zytiga for mCRPC.
enzalutamide or abiraterone in men with mCRPC selected for BRCA 1/2 or ATM gene mutations, a subpopulation of HRR gene mutations.
enzalutamide or abiraterone in men with mCRPC selected for BRCA1/2 or ATM gene mutations, a subpopulation of HRR gene mutations.
Recommendations on management options for newly diagnosed mCSPC or mCRPC were extracted from full-text and synthesized for review.
Predictive biomarkers of tumor sensitivity to STEAP1 antibody-drug conjugate (ADC) in patients (pts) with metastatic castration resistant prostate cancer (mCRPC).
CI: Guven araligi, FU: Odaklanmis ultrason COU-AA-302 faz III calismasinda 1088 kemo-naif, asemptomatik veya hafif semptomatik mCRPC hastasi degerlendirildi.
Rahul Aggarwal, M.D., from the University of California in San Francisco, and colleagues performed metastatic tumor biopsy of 202 patients with progressive mCRPC. The specimens underwent independent, blinded pathology review and RNA/DNA sequencing.
Scarpi et al., "Systemic immune-inflammation index predicts the clinical outcome in patients with mcrpc treated with abiraterone," Frontiers in Pharmacology, vol.
We investigated the role of osteopontin (OPN) and stathmin-1 (STHMN1) in metastatic castrate-resistant (mCRPC).
Beja et al., "A randomized phase II cross-over study of abiraterone + prednisone (ABI) vs enzalutamide (ENZ) for patients (pts) with metastatic, castration-resistant prostate cancer (mCRPC)," Journal of Clinical Oncology, vol.
Recently, a number of studies confirmed that PSMA serves as a good target for molecular imaging in PET examinations [21, 22] and potential targets in the treatment of metastatic castration-resistant prostate cancer (mCRPC) [23].
Enzalutamide will help patients with metastatic castration-resistant prostate cancer (mCRPC) who still show signs of the condition after going through androgen deprivation therapy.